FAIR VALUE - Narrative (Details)		3 Months Ended		6 Months Ended
	May 20, 2020 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Fair value of contingent consideration		$ 1,300,000	$ 2,195,000	$ 2,945,000	$ 1,602,000
Revenue volatility
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.35		0.35
Discounted Cash Flow | Discount rate
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.085		0.085
Discounted Cash Flow | Credit spread
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input		0.078		0.078
Zyla Life Sciences
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, royalty percentage	20.00%
CAMBIA
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration		$ 200,000		$ 200,000		$ 200,000
INDOCIN | Zyla Life Sciences | Iroko
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent payment consideration, future royalties covenant, product net sales (over)	$ 20,000,000